


# Hepatitis C in Indiana

**Deborah Nichols, MPH, MS**  
*Viral Hepatitis/Harm Reduction Program Director*

OU D ECHO  
 Medical Co-Morbidity Sessions  
 October 23, 2019



## Mission and Vision

**Mission:**  
 To promote, protect, and improve the health and safety of all Hoosiers

**Vision:**  
 A healthier and safer Indiana







- Train with staff from Step-Up, Inc., Fairbanks School of Public Health, and the Indiana State Department of Health
- Facilitate health workshops to educate your peers
- Develop marketable career skills and receive reentry services
- Connect with, and learn from, peer educators at IDOC facilities around the state through monthly videoconferences
- Routinely receive continuing education
- Make a difference in your community

For more information, or to get involved, please speak with your case worker!

Prison Health | Community Health


## How do you get it?




# Blood-to-Blood



## Hepatitis C is NOT transmitted



BY TOUCHING    THROUGH FOOD    FROM KISSING    BY INSECT BITES    IN THE POOL



## How do you know you have it?


# Get tested!




## Can it be treated or cured?

**YES!** **YES!**

**YES!** **YES!**



## HCV Treatments

Treatment	Genotypes	Duration	Cost
EPCLUSA	ALL	12 WEEKS	\$84,000-\$94,500
HARVONI	1	8, 12 or 24 WEEKS	\$26,400
SOVALDI & DAASIVIA	1 & 3	12 on 24 WEEKS*	\$26,400
SOVALDI & SOVALDI	2	12 WEEKS	\$26,400
VEDIRA DAK	1	12 on 24 WEEKS*	\$26,400
ZEPATIER	1 & 4	12 on 16 WEEKS*	\$26,400

Generics now available for \$24,500

<http://www.hepatitiswa.com.au/2017/08/01/new-hep-c-treatments-infographic/>

## What can happen if you don't get it treated or cured?

### PROGRESSION OF LIVER DAMAGE

HEALTHY LIVER	FIBROTIC LIVER	CIRRHOTIC LIVER	LIVER CANCER
			
A healthy liver is able to perform its normal functions effectively (e.g. adding oxygen and breaking down harmful drugs and poisons).	Continuous inflammation of the liver caused by hepatitis C can lead to fibrosis—the formation of scar tissue within the liver.	Extensive scarring can block the flow of blood through the liver and cause liver function to deteriorate over time—this is called cirrhosis.	Hepatitis C is a leading cause of liver cancer—the formation of a malignant tumour in the liver.




## How can you prevent others from getting it or giving it to others?

**A**bstain

**B**e faithful

**C**hange Harm Reduction

### Lessons in chronic health care learned through Project ECHO at Henderson prison



I am here to challenge each and every one of you

Be a voice of the people  
 Make a difference  
 To pour love out, the inside answer to the outside problem  
 I became empowered/feel part of a community  
 I am ready for a challenge


Live a disease-free life

I don't want to be shackled to my past anymore  
 Help someone stand up  
 We all have a better destiny


**This will make a difference**

I am worth something  
 I am the difference maker  
 Become part of the solution  
 Become better as a person  
 I'm giving back

Be the change you wish to see in the world  
 I want to be a stepping stone for you to get where you are going  
 When I talk, people listen  
 Fear is contagious, but so is hope  
 Be of assistance to everybody, including myself!



## Viral Hepatitis Surveillance




I THINK WE SHOULD GIVE IT ANOTHER SHOT.

WE SHOULD SPEAK UP AND I CAN PROVE IT.


OUR RELATIONSHIP

HUH.

MAYBE YOU'RE RIGHT. I KNOW DIRT WOULD CONVINCE YOU. NO, I JUST THINK I CAN DO BETTER THAN SOMEONE WHO DOESN'T LABEL HER AXES.








26 people  
per day  
in Indiana  
in 2018  
received their first  
reactive HCV test



20 babies  
in Indiana  
in 2018  
had a confirmed  
surveillance  
case of  
hepatitis C

13%

13% of all new cases of  
hepatitis C cases in Indiana in  
2018 were identified in  
Department of Corrections



### Hepatitis C Lab Reporting

**Required**

- All positive screening tests are reportable (antibody including rapid tests)
- All positive confirmatory tests are reportable (RNA, Genotype)

**Desired**

- Pregnancy status for women of child bearing age
- Bilirubin levels
- ALT levels
- Symptoms consistent with VH
- Negative antibody results
- Negative RNA results

## 410 IAC 1-2.5-75-76


**Report immediately on suspicion (!) Hepatitis, viral, Type A**  
**Hepatitis, viral, Type B**  
**! Hepatitis, viral, Type B, pregnant woman (acute and chronic) or perinatally exposed infant**  
**Hepatitis, viral, Type C (acute), within five (5) business days**  
**Hepatitis, viral, Type Delta**  
**! Hepatitis, viral, Type E**  
**Hepatitis, viral, unspecified**

**Anti-HAV IgM, HBsAg, HBeAg, or IgM anti-HBc, Genotype, RNA (PCR, NAT), or anti-HCV Delta, Anti-HEV IgM and IgG.**

Report immediately on suspicion (!) Hepatitis, viral, Type A  
 Hepatitis, viral, Type B  
 Hepatitis, viral, Type B, pregnant woman (acute and chronic) or perinatally exposed infant  
 Hepatitis, viral, Type C (acute), within five (5) business days  
 Hepatitis, viral, Type Delta  
 Hepatitis, viral, Type E  
 Hepatitis, viral, unspecified

Anti-HAV IgM, HBsAg, HBeAg, or IgM anti-HBc, Genotype, RNA (PCR, NAT), or anti-HCV Delta, Anti-HEV IgM and IgG.

Report immediately on suspicion (!) Report within 24 hours (!). All others report within 72 hours or as noted.



## Hepatitis C Treatment

People who inject drugs represent a key population with the potential to sustain the HCV epidemic through continued transmission and thus **SHOULD** be targeted for treatment

## Barriers to HCV Treatment for PWID

- At the patient level, misinformation about HCV and its treatment and the stigma related to substance use and HCV infection hinder linkage to care and limit patient interactions with the healthcare system
- At the provider level, misguided concerns about reinfection risk and adherence to HCV therapies
- At the system level, limited HCV treatment sites and restrictions on access to HCV therapy

## Patient Level

- At the patient level, **innovative strategies** are needed to increase engagement in care for PWID.
- Peer support by others who have experienced substance use may be particularly effective at linking and supporting PWID through HCV treatment.
- HCV testing and linkage to HCV treatment in settings where PWID feel comfortable, potentially including sites where they currently access other services.

## Provider Level

- Trained non-specialists can independently provide HCV treatment through ongoing collaboration using telemedicine platforms such as the Project ECHO model.
- It is critical to integrate harm reduction such as access to syringe programs into HCV care.

## System Level

- Integrate HCV treatment into substance use disorder treatment programs, public health clinics, syringe service programs, community-based organizations, and other sites providing services to PWID has the additional benefit of reducing barriers to HCV treatment.
- Innovative payment models at the system level may also improve treatment uptake..

\*July 1, 2019 FSSA removed fibrosis restrictions for Medicaid patients for hepatitis C treatment

0

## Elimination!



*It's possible.*

*Thank you!*

To all the stakeholders in Indiana working to eliminate hepatitis!



## Thank you

**Deborah Nichols, MPH, MS**  
*Viral Hepatitis/Harm Reduction Program Director*  
Division of HIV/STD/Viral Hepatitis  
[denichols@isdh.in.gov](mailto:denichols@isdh.in.gov)

